Article

July 29, 2013

New Infographic from AHRQ on Hospital Readmission Rates

Check out this new infographic from the Agency for Healthcare Research and Quality's Healthcare Cost and Utilization Project.

Check out this new infographic from the Agency for Healthcare Research and Quality’s Healthcare Cost and Utilization Project. The infographic shows 30-day readmission rates to U.S. hospitals. Of particular note: the privately insured have lower readmission rates than Medicare and Medicaid beneficiaries.

Read the full story: http://bit.ly/13hNYjF

Source: Ameica's Health Insurance Plans - SmartBrief

Related Videos

Shawn Griffin, MD, sitting for a video interview

5 experts are featured in this series

5 experts are featured in this series

Christine Funke, MD

John Michael O'Brien, PharmD, MPH

Kathi Henson, MBA, sitting for a video interview

Mike Fazio, Navista, Cardinal Health

1 expert in this video

1 expert in this video

Related Content

Fillingoutaformforaclinicaltrial | Image Credit: © KayExam/peopleimages.com-stock.adobe.com

April 30th 2025

Keep Patients at the Center of Clinical Research

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

gene therapy | Image Credit: © RFBSIP - stock.adobe.com

April 30th 2025

Expanding Broader Patient Access to CGTs

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

FDA approved. | Image Credit: Pawel - stock.adobe.com

April 30th 2025

FDA Approves Nipocalimab for Generalized Myasthenia Gravis

Christina Mattina

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.

The complex interplay between RA and metabolic health can have a significant impact on morbidity and mortality and thus deserves attention, authors of a new review argued. | Image credit: 9nong - stock.adobe.com

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

Related Content

Fillingoutaformforaclinicaltrial | Image Credit: © KayExam/peopleimages.com-stock.adobe.com

April 30th 2025

Keep Patients at the Center of Clinical Research

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

gene therapy | Image Credit: © RFBSIP - stock.adobe.com

April 30th 2025

Expanding Broader Patient Access to CGTs

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

Managed Care Cast Thumbnail

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

FDA approved. | Image Credit: Pawel - stock.adobe.com

April 30th 2025

FDA Approves Nipocalimab for Generalized Myasthenia Gravis

Christina Mattina

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.

The complex interplay between RA and metabolic health can have a significant impact on morbidity and mortality and thus deserves attention, authors of a new review argued. | Image credit: 9nong - stock.adobe.com

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions